KLRA
Kailera Therapeutics, Inc. Common Stock
NASDAQ: KLRA · HEALTHCARE · BIOTECHNOLOGY
$25.15
+0.60% today
Updated 2026-05-01
Market cap
$3.21B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.26
Dividend yield
—
52W range
$16 – $28
Volume
1.8M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-122.30M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2025 | TTM |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Net income | $-148.96M | $-148.96M |
| EPS | — | $-1.26 |
| Free cash flow | $-122.30M | $-122.30M |
| Profit margin | — | — |
Peer comparison
Smart narrative
Kailera Therapeutics, Inc. Common Stock trades at $25.15. Our Smart Value Score of 22/100 indicates the stock is weak.
Frequently asked questions
What is Kailera Therapeutics, Inc. Common Stock's stock price?
Kailera Therapeutics, Inc. Common Stock (KLRA) trades at $25.15.
Is Kailera Therapeutics, Inc. Common Stock overvalued?
Smart Value Score 22/100 (Grade F, Strong Sell).
What is the price target of Kailera Therapeutics, Inc. Common Stock (KLRA)?
The analyst target price is $—, representing NaN% downside from the current price of $25.15.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-36.90%
Beta—
50D MA$24.42
200D MA$24.42
Shares out0.13B
Float0.00B
Short ratio—
Avg volume1.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—